Hemodynamic and Metabolic Effects of Transdermal Clonidine in Patients With Hypertension and Non–Insulin-Dependent Diabetes Mellitus

The aim of this study was to evaluate the effect of transdermal clonidine on hemodynamic and metabolic parameters in patients who have elevated blood pressure and non–insulin-dependent diabetes mellitus (NIDDM). After a 2- week run in placebo period, 20 NIDDM patients who had diastolic blood pressure in the range of 90 to 105 mm Hg underwent a randomized, single blind, placebo controlled, cross-over study of 4 week treatment with clonidine (transdermal patch 2.5 mg/week) or placebo (inactive patch). Compared with placebo, clonidine significantly reduced systolic (153 ± 6 v 163 ± 8) and diastolic (88 ± 2 v 98 ± 3.5 mm Hg, P = .001) blood pressure, left ventricular mass (94 ± 11 v 99 ± 12 g/m2, P< .01) and fasting glucose levels. Total glucose disposal (glucose clamp) was 6.5 ± 1.5 with placebo and 7.1 ± 1.6 mg/kg/min with clonidine (P< .01). Oxidative glucose disposal (indirect calorimetry) was also greater after clonidine. Plasma glucose, insulin, and C-peptide responses following oral glucose (75 g) were significantly lower after clonidine, as well as urinary albumin excretion. Transdermal clonidine is effective in reducing blood pressure in hypertensive NIDDM patients and is well tolerated. It may be useful to reduce the cardiovascular impact of hypertension in diabetes mellitus.